REX Financial’s Bill Birmingham explains why peptides offer opportunities beyond GLP-1 weight-loss drugs, with potential across chronic diseases and significant room for growth. He breaks down the PEP ETF’s exposure to Eli Lilly (LLY), Novo (NVO) and emerging peptide companies like Viking Therapeutics (VKTX), Protagonist Therapeutics (PTGX) and Ascendis Pharma (ASND). Birmingham also distinguishes FDA-regulated treatments from gray-market peptides and discusses how new therapies, supply constraints and M&A could drive the peptide market higher.
======== Schwab Network ========
Empowering every investor and trader, every market day.
Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribe
Download the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185
Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7
Watch on Sling - https://watch.sling.com/1/channel/bb1b75050268416e82a557ff6387bff3/browse
Watch on Vizio - https://www.vizio.com/en/watchfreeplus/catalog/live-tv-channels/3123029569/schwab-network
Watch on DistroTV - https://www.distro.tv/live/schwab-network/
Follow us on X – https://twitter.com/schwabnetwork
Follow us on Facebook – https://www.facebook.com/schwabnetwork
Follow us on LinkedIn - https://www.linkedin.com/company/schwab-network/
About Schwab Network: https://schwabnetwork.com/about
Podden och tillhörande omslagsbild på den här sidan tillhör
Schwab Network. Innehållet i podden är skapat av Schwab Network och inte av,
eller tillsammans med, Poddtoppen.
